Real World Evidence Solutions Market

Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End Users, & Region, Business Model - Global Forecast to 2029

Report Code: HIT 6444 Feb, 2024, by marketsandmarkets.com

The global real world evidence solutions market in terms of revenue was estimated to be worth $2.0 Billion in 2024 and is poised to reach $4.5 Billion by 2029, growing at a CAGR of 16.5% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth of the market is mainly driven by growing prevalence of chronic illnesses, increasing shift towards value-based care, and potential of RWE in lessening drug development cost and expediting the drug development process.

Global Real world Evidence Solutions Market Trends

Real-world Evidence Solutions Market

To know about the assumptions considered for the study, Request for Free Sample Report

Real-world Evidence Solutions Market

Global Real-World Evidence Solutions Market Dynamics

DRIVER: Shift from volume to value-based care

The future of healthcare is shifting towards more quality-oriented, centering towards quality of services provided. Many hospitals understand the inability of traditional approaches in patient care, and cost effectiveness. Thus, healthcare is undergoing transformation through volume to Value-based care, which focuses on result-oriented data. As per American Journal of Managed Care, the value-based care practice is the method used for refinement of quality of life using healthcare inventions. These interventions are identified by using sets of standard parameters that are utilized in assessing the value and cost effectiveness. Thus, most of the hospitals are understanding the ineffectiveness of traditional approaches in patient care which is leading them to shift towards value-based care. Moreover, policymakers persist in endorsing value-based pricing mechanisms like the Value-Based Payment Modifier (VBPM) and the Center for Medicaid and Medicare Innovation (CMMI).

OPPORTUNITY: Growing Opportunities in emerging markets

The RWE solutions market is poised for substantial growth during the forecast period, with emerging economies with India, China, and Southeast Asian nations offering abundant opportunities. As the emerging markets possess vast, yet often underutilized, healthcare databases and patient repositories the availability of these untapped data sources has opened doors for RWE solutions to provide valuable insights into the practical use and outcomes of medical interventions. As the healthcare systems in these markets are undergoing rapid evolution and improvement, there is a simultaneous push toward enhanced data collection through electronic health records (EHRs) and other real-world data sources. This evolution has not only supported the growth of RWE but has also aligned the broader global trend towards data-driven healthcare. Additionally, increasing number of clinical trials in emerging countries is expected to pose a significant opportunity in the RWE solution market.

CHALLENGE: Shortage of skilled professionals

The growth of the real-world evidence solutions market is hindered by a shortage of skilled professionals capable of handling advanced digital solutions. There is a gap between the available and required skilled workforce in the clinical research industry, impeding the adoption and utilization of complex and hard software solutions in clinical trials. To address this challenge, the development of user-friendly software solutions presents a valuable growth opportunity for software vendors in this market. Thus, CROs and pharma companies, are facing constraints and escalating cost pressures to increase the training for their research staff. Moreover, the dynamic landscape of the global pharmaceutical and medical device, R&D outsourcing industries requires highly skilled professionals to adapt to ongoing changes in technologies. These experts must not only keep up with the advancements but also have to deliver high-quality services while adhering to good laboratory practices. This scarcity of skilled professionals has the potential to impede the adoption of new technologies potentially limiting the growth of the RWE solutions market.

Real-world Evidence Solutions Industry Ecosystem

The market map of RWE solutions Market ecosystem involves the components within this market. This defines these elements with an analysis of parameters involved. This involves datasets and services utilized in the field, outlining their applications across various therapeutic areas and among diverse end users. The product segment involves all datasets and services utilized by industries, healthcare payers, and providers. The vendors of various RWE solutions encompass organizations engaged in the entire research, product development, optimization, and launch processes. Some companies leverage scaled-up cloud platforms to construct automated pipelines, repositories of analytical assets, and visualizations accessible to multiple stakeholders’ groups. Other companies develop platforms generating evidence across indications, therapies, and use cases, enabling numerous analyses across multiple patient outcomes and thousands of subpopulations. These evidence generation engines deploy advanced and traditional RWE analytics side-by-side to extract insights into disease biology, unmet needs, real-world therapy usage, safety, effectiveness, and other factors that are crucial for informed decision-making. The primary stakeholders in RWE solutions market are the end users, while investors or funders and regulatory authorities exert significant influences in this arena.

Real-world Evidence Solutions Market Ecosystem

The Service segment accounted for the largest share of the real world evidence solutions industry in 2023.

By component, the real world evidence solutions market is segmented into services and data sets. The Service segment accounted for the largest market share in 2023. The service segment covers advanced analytics and consulting services. These services deliver insights to stakeholders and end users by extracting meaningful patterns of information and by delivering patient-centered outcomes. Moreover, the large share of this segment can be attributed to the surge in demand for converting the data into actionable evidence, coupled with the imperative to minimize delays in drug development, and the abundance of extensive healthcare data, are pivotal factors propelling the expansion of this market segment.

The drug development and approvals segment accounted for the largest share of real world evidence solutions industry in 2023.

Based on application, the real world evidence solutions market is segmented into drug development and approvals, medical device development and approvals, post market surveillance, market access and reimbursement/coverage decision making, Clinical & regulatory decision making. The drug development and approvals subsegments dominate this application segment in 2023. The drug development and approvals segment is categorized into oncology, neurology, cardiovascular diseases, immunology, and other therapeutic areas. Among these oncology sub segmented accounted largest share in 2023, attributed to increasing clinical trials conducted on medicines that are used to treat cancer. Moreover, several companies are increasing their investment in R&D for the innovation of new oncology drugs, leading to increase in segmental growth.

Pharmaceutical and medical device companies accounted for the largest share of the real world evidence solutions industry in 2023.

Based on end-users, the real world evidence solutions market is segmented into pharmaceutical and medical devices companies, healthcare payers, healthcare providers, and other end-users which includes CROs, academic institutions, patient advocacy groups, and HTA agencies. The pharmaceutical and medical devices companies dominate the end-user segment of RWE solutions market attributing to increase in adoption of RWE in these companies. This is due to its use in achieving regulatory compliances. Additionally, it has also helped in meeting the demands by the payers related to HEOR (Health Economics and Outcomes Research). Moreover, RWE data is essential for new drugs to navigate successfully through clinical trials. Thus, the efficacy of phase transition relies heavily on robust real-world outcomes. As stated in the 2011-2020 BIO industry analysis report, a mere 7.9% of drug development programs successfully reach the market, prompting pharmaceutical companies to increasingly embrace the adoption of RWE.

North America accounts the largest share of real world evidence solutions industry in 2023.

Real-world Evidence Solutions Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Based on the region, the real world evidence solutions market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. In 2023 North America accounted for the largest share of the real-world evidence solutions market. APAC region is expected to grow at the highest CAGR in the forecasted period. As this region are characterized by a rapidly expanding healthcare landscape with a growing population, rising prevalence of chronic diseases, and an increasing focus on improving healthcare infrastructure. Additionally, countries such as China and Japan in the region have a well-established clinical trial infrastructure, robust healthcare capabilities, strong medical workforce, and stringent quality standards, which is supporting the market growth in Asia Pacific. 

Prominent players in real-world evidence solutions markt include IQVIA HOLDINGS INC. . (US), Merative(US), Optum Inc. (US), Icon Plc. (Ireland), Syneos Health (US), Parexel International Corporation (US), ELEVANCE HEALTH, INC. (US), SAS Institute Inc. (US), Aetion Inc. (US), Trinetx Llc. (US), Trinity (US), PerkinElmer, Inc. (US), COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION (US), Clinigen Group plc (UK), Cegedim Health Data (France), Verantos (US), HealthVerity, Inc. (US), Datavant (US), Syapse, Inc. (US), Tempus (US), Flatiron Health (US), Thermo Fisher Scientific Inc. (US), LABORATORY CORPORATION OF AMERICA HOLDINGS (US), Oracle (US), and Medspace Holdings Inc. (US)

Scope of the Real World Evidence Solutions Industry

Report Metric

Details

Market Revenue in 2023

$2.0 Billion

Projected Revenue by 2029

$4.5 Billion

Revenue Rate

Poised to Grow at a CAGR of 16.5%

Market Driver

Shift from volume to value-based care

Market Opportunity

Growing Opportunities in emerging markets

The study categorizes the real world evidence solution market to forecast revenue and analyze trends in each of the following submarkets:

By Components

  • Real-World Evidence Solution, Service
  • Real-World Evidence Solution, Data sets
  • Disparate Data sets
  • Clinical settings data
  • Claims data
  • Pharmacy data
  • Patient-powered data
  • Other data sets
  • Integrated Data sets

By Application

  • Drug development and approvals
  • Oncology
  • Cardiovascular diasease
  • Neurology
  • Immunology
  • Other therapeutic areas
  • Medical device development and approvals
  • Post-market surveillance
  • Market access and reimbursement/coverage decision making
  • Clinical and regulatory decision making

By Mode of Deployment

  • On -premises
  • Cloud Based

By Revenue Model

  • Pay Per Usage (Value-Based Pricing)
  • Subscription
  • Real-World Evidence Solution market, by end-User
  • Pharmaceutical and medical device companies
  • Healthcare payers
  • Healthcare providers
  • Other end users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • Rest of Middle East and Africa

Recent Developments of Real World Evidence Solutions Industry:

  • In August 2023, Parexel (US) announced a strategic collaboration with Partex NV (Germany) to leverage artificial intelligence powered solutions and accelerate drug discovery and development for biopharmaceutical customers worldwide. This collaboration aims to improve outcomes for patients and create an environment of continues innovation in leveraging advanced technology, data-driven insights and collaborative ecosystem.
  • In June 2022, Franscisco Partners (US) acquired IBM Watson Health Business (US) and formed a new standalone company named Merative. This acquisition will help Merative in expanding reach of the healthcare data analytics products and improving healthcare delivery, decision making and performance.
  • In February 2022, Parexel International Corporation (US) partnered with n-Lorem Foundation (US) to improve and streamline the therapeutic development efforts of n- Lorem. This partnership will help the Parexel International Corporation in providing clinical operations, real-world data solutions, and expertise, including medical and regulatory.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION 
    1.1 OBJECTIVES OF THE STUDY 
    1.2 MARKET DEFINITION 
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY 
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
    1.7 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY 
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
    2.3 RESEARCH METHODOLOGY DESIGN 
    2.4 MARKET SIZE ESTIMATION 
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 
    2.6 RESEARCH ASSUMPTIONS  
    2.7 RISK ASSESSMENT  
    2.8 RESEARCH LIMITATIONS 
           2.8.1 METHODOLOGY-RELATED LIMITATIONS 
           2.8.2 SCOPE-RELATED LIMITATIONS 
    2.9 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY 
 
4 PREMIUM INSIGHTS 
 
5 MARKET OVERVIEW 
    5.1 MARKET DYNAMICS  
           5.1.1 DRIVERS 
           5.1.2 RESTRAINTS 
           5.1.3 OPPORTUNITIES 
           5.1.4 CHALLENGES 
    5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
    5.3 INDUSTRY TRENDS 
    5.4 ECOSYSTEM ANALYSIS 
    5.5 VALUE CHAIN ANALYSIS 
    5.6 TECHNOLOGY ANALYSIS  
    5.7 TARIFF AND REGULATORY LANDSCAPE  
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 
           5.7.2 REGULATORY ANALYSIS 
                    5.7.2.1 North America 
                               5.7.2.1.1 US 
                               5.7.2.1.2 Canada 
                    5.7.2.2 Europe 
                    5.7.2.3 Asia Pacific 
                               5.7.2.3.1 Japan 
                               5.7.2.3.2 China 
                               5.7.2.3.3 India 
    5.8 PRICING ANALYSIS 
           5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY SOFTWARE
           5.8.2 AVERAGE SELLING PRICE TREND, BY REGION 
    5.9 PORTER’S FIVE FORCES ANALYSIS 
    5.10 PATENT ANALYSIS 
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA  
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 
           5.11.2 BUYING CRITERIA 
    5.12 END USER ANALYSIS 
           5.11.1 UNMET NEEDS
           5.11.2 END USER EXPECTATIONS 
    5.13 KEY CONFERENCES & EVENTS IN 2024-2025 
    5.14 REAL WORDLD EVIDENCE SOLUTION INVESTMENT LANDSCAPE 
    5.15 REAL WORDLD EVIDENCE SOLUTION BUSINESS MODELS 
    5.16 USE CASES/CASE STUDIES 
 
6 REAL WORDLD EVIDENCE SOLUTION MARKET, BY COMPONENT 
    6.1 INTRODUCTION 
    6.2 SERVICES 
    6.3 DATA SETS 
           6.3.1 DISPARATE DATA SETS
                    6.3.1.1 CLINICAL SETTING DATA SETS
                    6.3.1.2 CLAIMS DATA SET
                    6.3.1.3 PHARMACY DATA SET
                    6.3.1.4 PATIENT-POWERED DATA SET
                    6.3.1.5 REGISTRY-BASED DATA SETS
           6.3.2 INTEGRATED DATA SETS
 
7 REAL WORDLD EVIDENCE SOLUTION MARKET, BY APPLICATION 
    7.1 INTRODUCTION  
    7.2 DRUG DEVELOPMENT AND APPROVALS 
           7.2.1 ONCOLOGY
           7.2.2 CARDIOVASCULAR DISEASE
           7.2.3 NEUROLOGY
           7.2.4 IMMUNOLOGY
           7.2.5 OTHER THERAPEUTIC AREAS
    7.3 MEDICAL DEVICE DEVELOPMENT AND APPROVALS 
    7.4 POST-MARKET SURVELLIANCE 
    7.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 
    7.6 CLINICAL AND REGULATORY DECISION MAKING 
    7.7 OTHERS (IF ANY) 
 
8 REAL WORDLD EVIDENCE SOLUTION MARKET, BY REVENUE MODEL 
    8.1 PAY PER USAGE (VALUE-BASED PRICING) 
    8.2 SUBSCRIPTION  
 
9 REAL WORLD EVIDENCE SOLUTION MARKET, BY MODE OF DEPLOYMENT 
    9.1 ON-PREMISE 
    9.2 CLOUD-BASED 
 
10 REAL WORDLD EVIDENCE SOLUTION MARKET, BY ENDUSER 
     10.1 INTRODUCTION 
     10.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 
     10.3 HEALTHCARE PAYERS 
     10.3 HEALTHCARE PROVIDERS 
     10.4 OTHER END USERS (CROS, ACADEMIC INSTITUTES, REGULATORY AUTHORITIES, PATIENT ADVOCACY GROUPS, AND HTA AGENCIES) 
 
11 REAL WORDLD EVIDENCE SOLUTION MARKET, BY REGION  
     11.1 INTRODUCTION  
     11.2 NORTH AMERICA  
             11.2.1 US 
             11.2.2 CANADA 
             11.2.3 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION
     11.3 EUROPE  
             11.3.1 GERMANY 
             11.3.2 FRANCE 
             11.3.3 UK 
             11.3.4 ITALY 
             11.3.5 SPAIN 
             11.3.6 REST OF EUROPE 
             11.3.7 EUROPE: IMPACT OF ECONOMIC RECESSION
     11.4 ASIA PACIFIC  
             11.4.1 CHINA 
             11.4.2 JAPAN 
             11.4.3 INDIA 
             11.4.3 REST OF ASIA PACIFIC
             11.4.5 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION
     11.5 LATIN AMERICA  
             11.5.1 BRAZIL
             11.5.2 MEXICO
             11.5.3 REST OF LATIN AMERICA
             11.5.4 LATIN AMERICA: IMPACT OF ECONOMIC RECESSION
     11.6 MIDDLE EAST AND AFRICA  
             11.6.1 GCC COUNTRIES
             11.6.2 REST OF MIDDLE EAST & AFRICA
             11.6.3 MIDDLE EAST & AFRICA: IMPACT OF ECONOMIC RECESSION
 
12 COMPETITIVE LANDSCAPE  
     12.1 OVERVIEW  
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS  
     12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS  
     12.4 MARKET SHARE/RANKING ANALYSIS  
     12.5 BRAND/SOFTWARE COMPARATIVE ANALYSIS 
     12.6 VALUATION AND FINANCIAL METRICS OF KEY REAL WORDLD EVIDENCE SOLUTION VENDORS 
     12.7 COMPANY EVALUATION MATRIX 
             12.7.1 STARS 
             12.7.2 EMERGING LEADERS 
             12.7.3 PERVASIVE PLAYERS 
             12.7.4 PARTICIPANTS 
             12.7.5 COMPANY FOOTPRINT
     12.8 START- UP/SME EVALUATION MATRIX 
             12.8.1 PROGRESSIVE COMPANIES 
             12.8.2 RESPONSIVE COMPANIES 
             12.8.3 DYNAMIC COMPANIES
             12.8.4 STARTING BLOCKS
             12.8.5 COMPETITIVE BENCHMARKING
     12.9 COMPETITIVE SCENARIO AND TRENDS 
             12.11.1 PRODUCT LAUNCHES
             12.11.2 DEALS
             12.11.3 OTHERS
 
13 COMPANY PROFILES 
     13.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) *
             13.1.1 IQVIA HOLDINGS INC.
             13.1.2 MERATIVE
             13.1.3 OPTUM INC. (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.)
             13.1.4 ICON PLC.
             13.1.5 SYNEOS HEALTH, INC.
             13.1.6 PAREXEL INTERNATIONAL CORPORATION
             13.1.7 THERMO FISHER SCIENTIFIC INC.
             13.1.8 LABCORP HOLDINGS
             13.1.9 ORACLE CORPORATION
             13.1.10 ELEVANCE HEALTH
             13.1.11 SAS INSTITUTE
             13.1.12 AETION INC.
             13.1.13 TRINETX LLC
             13.1.14 TRINITY LIFE SCIENCES
             13.1.15 PERKINELMER INC
             13.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION
     13.2 OTHER KEY PLAYERS 
             13.2.1 CLINIGEN
             13.2.2 CEGEDIM HEALTH DATA
             13.2.3 VERANTOS INC.
             13.2.4 MEDPACE HOLDINGS INC.
             13.2.5 HEALTHVERITY INC.
             13.2.6 DATAVANT. 
             13.2.7 SYAPSE INC.
             13.2.8 TEMPUS LABS INC.
             13.2.9 FLATIRON HEALTH
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
14 APPENDIX 
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 AVAILABLE CUSTOMIZATIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

The study involved five major activities to estimate the current size of the Real-World Evidence Solution market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the study of Real-World Evidence Solution Market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply side and demand side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, biostatisticians, and related key executives from various companies and organizations operating in the Real-World Evidence Solution market. Primary sources from the demand side included industry experts, such as directors of pharmaceutical, biopharmaceuticals, and medical device companies, contract manufacturing organizations, directors of RWE vendor companies, directors of clinical research organizations, and other related key executives.

The following is a breakdown of the primary respondents:

Breakdown of Primary Participants:

Real-world Evidence Solutions Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers of companies are defined on the basis of their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Real-World Evidence Solution market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global Real-World Evidence Solution Market Size: Bottom-Up Approach

Real-world Evidence Solutions Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global Real-World Evidence Solution Market Size: Top-Down Approach

Real-world Evidence Solutions Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Real-World Evidence Solution Market.

Market Definition:

Real-world evidence comprises clinical evidence generated through the analysis of real-world data (RWD) pertaining to the utilization, as well as the potential advantages or risks, of medical products. RWD is specifically described as data originating from diverse sources linked to results within a varied patient population in real-world environments.

Key Stakeholders

  • Original Equipment manufacturers
  • Pharmaceutical and biotechnology companies
  • Medical device companies
  • Clinical laboratories
  • Contract research organizations
  • Medical device research and consulting firms
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors
  • Hospitals and clinics
  • Insurers
  • Academic medical centers
  • Government research organizations
  • Contract and research organizations
  • Regulatory agencies.

Report Objectives

  • To define, describe, and forecast the global Real-World Evidence Solution market on the basis of components, application, end user, and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and to provide details of the competitive landscape for market leaders.
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. (along with major countries in these regions)
  • To profile the key players and comprehensively analyze their market shares and core competencies in the RWE solutions market.
  • To track and analyze competitive developments such as business expansions, partnerships, agreements, and collaborations; mergers& acquisitions; and new product/service launches in the global RWE solutions market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company.
  • Geographic Analysis:  Further breakdown of the Latin American Real-World Evidence Solution into specific countries and, the Middle East, and Africa Real-World Evidence Solution into specific countries and further breakdown of the European Real-World Evidence Solution into specific countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
HIT 6444
Published ON
Feb, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Real World Evidence Solutions Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback